Pharma Focus Europe
Worldwide Clinical Trials || Tailored Clinical Solutions
Latest Issue
Get instant access to latest e-book

LATEST NEWS


Dec 2023

NextPoint Therapeutics' NPX887 Clears FDA IND for Reactivating Immune Cells in HHLA2+ Solid Tumors

NextPoint Therapeutics a biotechnology company in the clinical stage has disclosed the acceptance of its investigational new drug application by the US Food Drug Administration


Dec 2023

FDA Clears Vittoria Biotherapeutics' IND Application for VIPER-101 to Address T-Cell Lymphoma

Vittoria Biotherapeutics has achieved a significant milestone with the clearance of its Investigational New Drug application by the US Food and Drug Administration This clearance paves the way for the initiation


Dec 2023

Velocity Clinical Research Extends Its Operations Into Poland

Velocity Clinical Research a renowned organization specializing in clinical research across diverse medical fields has announced its expansion into Poland through the acquisition of its inaugural center ClinMedica Research


Dec 2023

Philogen S.p.A. Receives GMP Certification for New Production Facility in Rosia, Italy

Philogen SpA is thrilled to announce that its new GMP facility in Rosia Siena has received GMP certification The Agenzia Italiana del Farmaco


Dec 2023

Rumi Scientific and X-Chem Collaborate to Advance Lead Candidate in Huntington’s Disease Research

Rumi Scientific a company focused on developing therapies for rare and neurodegenerative diseases using its high throughput organoid phenotypic screening platform has announced a collaboration with XChem


Dec 2023

Acino Successfully Finalizes the Acquisition of M8 Pharmaceuticals, Significantly Expanding Its Presence and Capabilities in Latin America

Acino a Swiss pharmaceutical company based in Zurich has recently finalized the acquisition of M Pharmaceuticals a rapidly growing specialty biopharmaceutical firm headquartered in Mexico City M focuses on licensing

press releases

Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis

Basilea Pharmaceutica Ltd Allschwil a commercialstage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections announced today that its license partner Astellas Pharma US Inc

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for the Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (Pedal) Master Clinical Trial

Kura Oncology Inc a clinicalstage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer and The Leukemia Lymphoma Society

Effector Therapeutics Announces New Positive Interim Data From Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients

EFFECTOR Therapeutics Inc a leader in the development of selective translation regulator inhibitors for the treatment of cancer today announced new positive interim data from dose escalation

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare Cholestatic Liver Disease, PBC

Ipsen and GENFIT today announced that the US Food and Drug Administration has accepted the New Drug Application for investigational elafibranor

25 - 26

Nov 2023

13 - 13

Dec 2023

14 - 15

Dec 2023

02 - 02

Jan 2024

02 - 02

Jan 2024

Drug Action in Pharmacy

Freeport, Bahamas

05 - 05

Jan 2024
ROUQETTE - Pharma Virtual Lab
3rd Allogeneic Cell Therapies Summit Europe - Pharma Focus Banenr



  • Techno Trends

    Eli Lilly's New Drug Mounjaro™ to Treat Type 2 Diabetes

    Mounjaro tirzepatide injection developed by Eli Lilly and Company is a novel dualtargeted therapy that has been demonstrated to enhance glycemic control in adult patients with type diabetes In people with type diabetes a onceweekly glucosedependent insulinotropic polypeptide GIP and glucagonlike peptide